Merck Announces Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Merck (MRK) to Acquire cCAM Biotherapeutics in ~$605M Deal
July 28, 2015 7:58 AM EDTMerck (NYSE: MRK) and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510 million associated with the attainment of certain clinical development, regulatory and commercial... More
Merck (MRK) Tops Q2 EPS by 5c; Narrows and Raise FY15 EPS Outlook
July 28, 2015 7:02 AM EDTMerck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.
Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.
Were investing resources... More
